Shifa Biomedical

Shifa Biomedical is a U.S.-based drug discovery company targeting cardiovascular disease with a focus on dyslipidemia. Its primary asset is P-21, a preclinical, orally bioavailable small molecule designed to inhibit PCSK9 and lower LDL cholesterol, positioning it as a potential first-in-class oral alternative to injectable monoclonal antibodies. The company is privately held, pre-revenue, and utilizes a hybrid discovery platform combining experimental and virtual screening. While the science is promising, Shifa faces significant risks typical of early-stage biotechs, including clinical development hurdles and intense competition in the lipid-lowering market.

Integrated drug discovery platform combining molecular biology, biochemistry, crystallography, and medicinal, computational, and combinatorial chemistry, with a focus on virtual and experimental screening for small molecule development.

Shifa competes in the crowded LDL-lowering market dominated by statins, ezetimibe, and injectable PCSK9 inhibitors (e.g., Amgen's Repatha, Sanofi/Regeneron's Praluent). Its direct competition comes from other companies pursuing oral PCSK9 inhibitors and novel oral mechanisms (e.g., CETP inhibitors), many of which have greater financial and development resources.